Key result
Chronic administration of diminazene aceturate at /kg/day for three weeks in spontaneously hypertensive rats decreased mean arterial pressure from 136 to 124 mmHg.
Why the study?
Does diminazene aceturate reduce mean arterial pressure in spontaneously hypertensive rats?
Does diminazene aceturate reduce mean arterial pressure in spontaneously hypertensive rats?
Answers are grounded in this paper and cite their sources.
Diminazene aceturate acts as a potent ACE2 activator that reduces blood pressure and cardiac hypertrophy in spontaneously hypertensive rats, suggesting potential as a novel antihypertensive agent.
Emerging evidence suggests that ACE2 could be a new therapeutic target for cardiovascular disease (CVD) and hypertension. In this study, we used a molecular docking strategy combined with in vitro functional screening to search for novel ACE2 activators in support of this concept. Enzymatic assays with top‐scoring compounds demonstrated that diminazene aceturate (DIZE), a known antiprotozoal drug used in humans, acts as a potent activator of ACE2. DIZE caused a dose‐dependent increase in ACE2 activity and a maximal increase of 2.5 fold (Vmax) was observed with 50 μM. Intravenous administration of DIZE in WKYs and SHRs caused a transient and dose‐dependent decrease in mean arterial pressure (MAP). Although, DIZE decreased MAP in both strains of rats, its efficacy was significantly higher in the SHRs; a dose of 5 mg/kg of DIZE triggered a MAP reduction of 50±9 mmHg in WKY rats (n=6) compared to 85±11 mmHg in SHRs (n=6). In addition, chronic administration of DIZE at 15 mg/kg/day for three weeks in SHRs caused a modest decrease in MAP (from 136±3 to 124±6 mmHg, p<0.05). This was associated with a reduction in the heart weight to body weight ratio (3.8±0.004 in control versus 3.6±0.018 in DIZE treated, p<0.005) and myocardial fibrosis. These data suggest that DIZE may serve as a lead compound for the discovery of next generation of drugs for the treatment of CVD and hypertension. This work was funded by NIH grant HL56921.
No takes yet. Share an insight, caveat, or question.
Gjymishka et al. (2010) studied Hypertension (animal model). Diminazene aceturate (DIZE) vs. Control / Baseline was evaluated on Mean arterial pressure (MAP) (p=<0.05). Chronic administration of diminazene aceturate at /kg/day for three weeks in spontaneously hypertensive rats decreased mean arterial pressure from 136 to 124 mmHg.
Synapse has enriched 10 related papers. Consider them for comparative context: